What question did this study set out to answer?

To review the major findings and clinical implications of the Stroke Prevention in Atrial Fibrillation (SPAF) trials regarding antithrombotic therapy.

May 20, 2003Annals of Internal Medicine

Lessons from the Stroke Prevention in Atrial Fibrillation Trials

View Full Paper

Ask AI

Bookmark

Why the study?

Do warfarin, aspirin, and their combination prevent stroke in patients with atrial fibrillation?

Population

3950 participants with atrial fibrillation across six multicenter trials

Design

Review

Authors

RHRobert G. HartUniversity of Vermont JHJonathan L. HalperinElectrophysiology LPLesly A. PearceElectrophysiology

Discussion

Member takes

Implication

Antithrombotic prophylaxis in atrial fibrillation should be individualized based on stroke risk, with warfarin for high-risk and aspirin for low-risk patients.

Key Points

To review the major findings and clinical implications of the Stroke Prevention in Atrial Fibrillation (SPAF) trials regarding antithrombotic therapy.
Synthesis of evidence from six multicenter clinical trials evaluating antithrombotic therapies in N=3950 participants with atrial fibrillation.
Assessment of warfarin, aspirin, and combination therapy using transesophageal echocardiography and the SPAF III stroke risk stratification scheme.
Warfarin inhibits atrial appendage thrombus formation and substantially prevents cardioembolic stroke in high-risk patients, whereas aspirin primarily prevents noncardioembolic stroke in low-risk patients.
Risk stratification categorizes approximately one third of patients as low risk (managed with aspirin) and one third as high risk (requiring warfarin), with women deriving greater benefit from anticoagulation than men.

Structured PICO

Do warfarin, aspirin, and their combination prevent stroke in patients with atrial fibrillation?

Population

3950 participants with atrial fibrillation across six multicenter trials

Intervention

Warfarin, aspirin, and their combination

Outcome

Strokehard clinical

Antithrombotic prophylaxis in atrial fibrillation should be individualized based on stroke risk, with warfarin for high-risk and aspirin for low-risk patients.

Cite This Study

Hart et al. (2003) studied this question.

synapsesocial.com/papers/6a82ddbe0715daaa1f23c2e4 https://doi.org/10.7326/0003-4819-138-10-200305200-00011

Topics

Atrial fibrillation Persistent AF management Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Implication

Antithrombotic prophylaxis in atrial fibrillation should be individualized based on stroke risk, with warfarin for high-risk and aspirin for low-risk patients.

Lessons from the Stroke Prevention in Atrial Fibrillation Trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Lessons from the Stroke Prevention in Atrial Fibrillation Trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider